DrugPatentWatch Database Preview
Details for Patent: 7,906,542
Which drugs does patent 7,906,542 protect, and when does it expire?
This patent has eighty-one patent family members in thirty-five countries.
Summary for Patent: 7,906,542
Title: | Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin |
Abstract: | Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. |
Inventor(s): | Viscomi; Giuseppe Claudio (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT) |
Assignee: | Alfa Wassermann, S.p.A. (Bologna, IT) |
Application Number: | 12/119,622 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; Formulation; |
Drugs Protected by US Patent 7,906,542
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 021361-001 | May 25, 2004 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | |||
Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 022554-001 | Mar 24, 2010 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 7,906,542
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
7,902,206 | Polymorphic forms .alpha., .beta. and .gamma. of rifaximin | ➤ Try a Free Trial |
7,915,275 | Use of polymorphic forms of rifaximin for medical preparations | ➤ Try a Free Trial |
7,923,553 | Processes for the production of polymorphic forms of rifaximin | ➤ Try a Free Trial |
7,045,620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 7,906,542
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 043547 | ➤ Try a Free Trial | |||
Argentina | 081991 | ➤ Try a Free Trial | |||
Argentina | 081992 | ➤ Try a Free Trial | |||
Austria | 361927 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |